Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium

Pharmacogenomics

Volumn 18, Issue 10, 2017, Pages 931-943

  Farzan, Niloufar ^a,b   Vijverberg, Susanne J ^a,b   Andiappan, Anand K ^c   Arianto, Lambang ^d   Berce, Vojko ^e,f   Blanca López, Natalia ^g   Bisgaard, Hans ^d   Bønnelykke, Klaus ^d   Burchard, Esteban G ^h   Campo, Paloma ⁱ   Canino, Glorisa ^j   Carleton, Bruce ^k   Celedón, Juan C ^l   Chew, Fook Tim ^m,ai   Chiang, Wen Chin ^m,ai   Cloutier, Michelle M ⁿ   Daley, Denis ^k   Den Dekker, Herman T ^o   Dijk, F Nicole ^p,q   Duijts, Liesbeth ^o   Flores, Carlos ^r,s   Forno, Erick ^l   Hawcutt, Daniel B ^t,u   Hernandez Pacheco, Natalia ^s   De Jongste, Johan C ^o   Kabesch, Michael ^v   Koppelman, Gerard H ^p,q   Manolopoulos, Vangelis G ^w   Melén, Erik ^x,y   Mukhopadhyay, Somnath ^z,aa   Nilsson, Sara ^x,y   Palmer, Colin N ^aa   Pino Yanes, Maria ^r,s   Pirmohamed, Munir ^u   Potočnki, Uros ^f   Raaijmakers, Jan A ^a   Repnik, Katja ^f   Schieck, Maximilian ^v,ab   Sio, Yang Yie ^m,ai   Smyth, Rosalind L ^ac   Szalai, Csaba ^ad,ae   Tantisira, Kelan G ^af,ag   Turner, Steve ^ah   Van Der Schee, Marc P ^b   Verhamme, Katia M ^o   Maitland Van Der Zee, Anke H ^a,b   more..

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c AGENCY FOR SCIENCE   (Singapore)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^f UNIVERSITY OF MARIBOR   (Slovenia)

^g HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^j UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^k UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^l CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^m NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

ⁿ UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^o ERASMUS MEDICAL CENTER   (Netherlands)

^p UNIVERSITY OF GRONINGEN   (Netherlands)

^q UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^r INSTITUTO DE SALUD CARLOS III   (Spain)

^s HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^t ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^u UNIVERSITY OF LIVERPOOL   (United Kingdom)

^v UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^w DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^x KAROLINSKA INSTITUTE   (Sweden)

^y STOCKHOLM COUNTY COUNCIL   (Sweden)

^z ROYAL ALEXANDRA CHILDREN S HOSPITAL   (United Kingdom)

^aa UNIVERSITY OF DUNDEE   (United Kingdom)

^ab HANNOVER MEDICAL SCHOOL   (Germany)

^ac UNIVERSITY COLLEGE LONDON   (United Kingdom)

^ad SEMMELWEIS UNIVERSITY   (Hungary)

^ae HEIM PÁL CHILDREN S HOSPITAL   (Hungary)

^af HARVARD MEDICAL SCHOOL   (United States)

^ag BRIGHAM AND WOMEN S HOSPITAL   (United States)

^ah UNIVERSITY OF ABERDEEN   (United Kingdom)

^ai KK Children's Hospital   (Singapore)

more..

Author keywords

asthma; children; consortium; genetics; pharmacogenomics; treatment

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; ANTIASTHMATIC AGENT;

ARTICLE; ASTHMA; CAUCASIAN; CHILD; DISEASE EXACERBATION; ETHNIC DIFFERENCE; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GEOGRAPHIC DISTRIBUTION; HUMAN; INTERNATIONAL COOPERATION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; ONLINE SYSTEM; OUTCOME ASSESSMENT; PHARMACOGENETICS; PHARMACOGENOMICS; QUESTIONNAIRE; TREATMENT DURATION; TREATMENT RESPONSE; ANCESTRY GROUP; ETHNOLOGY; GENETICS; GENOTYPE; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; PHARMACOGENETIC VARIANT; PROCEDURES; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CONTINENTAL POPULATION GROUPS; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL COOPERATION; MALE; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; RESEARCH DESIGN; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 85024501836     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs-2017-0035     Document Type: Article

References (60)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention (2016). www.ginasthma.org
2. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59(5), 469-478 (2004).
3. Szefler SJ, Martin RJ, King TS et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J. Allergy Clin. Immunol. 109(3), 410-418 (2002).
4. Szefler SJ, Phillips BR, Martinez FD et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol. 115(2), 233-242 (2005).
5. Malmstrom K, Rodriguez-Gomez G, Guerra J et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann. Intern. Med. Mar. 130(6), 487-495 (1999).
6. Langmack EL, Martin RJ. Heterogeneity of response to asthma controller therapy: clinical implications. Curr. Opin. Pulm. Med. 16(1), 13-18 (2010).
7. Bahadori K, Doyle-Waters MM, Marra C et al. Economic burden of asthma: a systematic review. BMC Pulm. Med. 9, 24 (2009).
8. Chapman KR, Boulet LP, Rea RM, Franssen E. Suboptimal asthma control: prevalence, detection and consequences in general practice. Eur. Respir. J. 31(2), 320-325 (2008).
9. Williams AE, Lloyd AC, Watson L, Rabe KF. Cost of scheduled and unscheduled asthma management in seven European Union countries. Eur. Respir. Rev. 15(98), 4-9 (2006).
10. Barnett SBL, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007. J. Allergy Clin. Immunol. 127(1), 145-152 (2011).
11. Fleming L, Wilson N, Bush A. Difficult to control asthma in children. Curr. Opin. Allergy Clin. Immunol. 7(2), 190-195 (2007).
12. Pijnenburg MW, Szefler S. Personalized medicine in children with asthma. Paediatr. Respir. Rev. 16(2), 101-107 (2015).
13. Park H-W, Dahlin A, Tse S et al. Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. J. Allergy Clin. Immunol. 133(3), 664.e5-669.e5 (2014).
14. Rogers AJ, Tantisira KG, Fuhlbrigge AL et al. Predictors of poor response during asthma therapy differ with definition of outcome. Pharmacogenomics 10(8), 1231-1242 (2009).
15. Wu AC, Tantisira K, Li L, Schuemann B, Weiss ST, Fuhlbrigge AL. Predictors of symptoms are different from predictors of severe exacerbations from asthma in children. Chest 140(1), 100-107 (2011).
16. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 429(6990), 464-468 (2004).
17. Yip VLM, Hawcutt DB, Pirmohamed M. Pharmacogenetic markers of drug efficacy and toxicity. Clin. Pharmacol. Ther. 98(1), 61-70 (2015).
18. Custovic A, Ainsworth J, Arshad H et al. The Study Team for Early Life Asthma Research (STELAR) consortium "Asthma e-lab": team science bringing data, methods and investigators together. Thorax 70(8), 799-801 (2015).
19. Bacharier LB, Boner A, Carlsen K-H et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 63(1), 5-34 (2008).
20. Pica consortium. www.pica-consortium.org
21. SurveyMonkey. www.surveymonkey.com/
22. Reddel HK, Taylor DR, Bateman ED et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am. J. Respir. Crit. Care Med. 180(1), 59-99 (2009).
23. Khalili B, Boggs PB, Shi R, Bahna SL. Discrepancy between clinical asthma control assessment tools and fractional exhaled nitric oxide. Ann. Allergy Asthma Immunol. 101(2), 124-129 (2008).
24. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam. Med. 37(5), 360-363 (2005).
25. R Development Core Team (2008). R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. www.R-project.org
26. Ferreira MAR, Matheson MC, Duffy DL et al. Identification of IL6R and chromosome 11q13.5 as risk loci for asthma. Lancet 378(9795), 1006-1014 (2011).
27. Palmer CNA, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 61(11), 940-944 (2006).
28. Wickman M, Melén E, Berglind N et al. Strategies for preventing wheezing and asthma in small children. Allergy 58(8), 742-747 (2003).
29. The Childhood Asthma Management Program (CAMP): design, rationale, and methods. Childhood Asthma Management Program Research Group. Control Clin. Trials 20(1), 91-120 (1999).
30. Bisgaard H. The Copenhagen Prospective Study on Asthma in Childhood (COPSAC): design, rationale, and baseline data from a longitudinal birth cohort study. Ann. Allergy Asthma Immunol. 93(4), 381-389 (2004).
31. Moffatt MF, Kabesch M, Liang L et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 448(7152), 470-473 (2007).
32. Nishimura KK, Galanter JM, Roth LA et al. Early-life air pollution and asthma risk in minority children. The GALA II and SAGE II studies. Am. J. Respir. Crit. Care Med. 188(3), 309-318 (2013).
33. Sonnenschein-van der Voort AMM, Jaddoe VW, Raat H et al. Fetal and infant growth and asthma symptoms in preschool children: the Generation R Study. Am. J. Respir. Crit. Care Med. 185(7), 731-737 (2012).
34. Pino-Yanes M, Sánchez-Machín I, Cumplido J et al. IL-1 receptor-associated kinase 3 gene (IRAK3) variants associate with asthma in a replication study in the Spanish population. J. Allergy Clin. Immunol. 129(2), 573-575, 575.e1-575.e10 (2012).
35. Koster ES, Raaijmakers JAM, Koppelman GH et al. Pharmacogenetics of anti-inflammatory treatment in children with asthma: rationale and design of the PACMAN cohort. Pharmacogenomics 10(8), 1351-1361 (2009).
36. Turner SW, Ayres JG, Macfarlane TV et al. A methodology to establish a database to study gene environment interactions for childhood asthma. BMC Med. Res. Methodol. 10, 107 (2010).
37. Hawcutt DB, Jorgensen AL, Wallin N et al. Adrenal responses to a low-dose short synacthen test in children with asthma. Clin. Endocrinol. (Oxf.) 84(5), 793 (2016).
38. Zuidgeest MGP, Koster ES, Maitland-van der Zee A-H et al. Asthma therapy during the first 8 years of life: a PIAMA cohort study. J. Asthma 47(2), 209-213 (2010).
39. Andiappan AK, Sio YY, Lee B et al. Functional variants of 17q12-21 are associated with allergic asthma but not allergic rhinitis. J. Allergy Clin. Immunol. 137(3), 758.e3-766.e3 (2016).
40. Berce V, Kozmus CEP, Potočnik U. Association among ORMDL3 gene expression, 17q21 polymorphism and response to treatment with inhaled corticosteroids in children with asthma. Pharmacogenomics J. 13(6), 523-529 (2013).
41. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev. Respir. Dis. 118(6 Pt 2), 1-120 (1978).
42. de Jongste J, Vrijlandt EJLE. Astma bijkinderen: samenvatting van de herziene rich-tlijnen van de Sectie Kinderlongziekten vande NVK. [Guideline "Asthma in Children"for pediatric pulmonologists]. Hilversum: SKL, (2007).
43. Han B, Eskin E. Random-effects model aimed at discovering associations in meta-analysis of genome-wide association studies. Am. J. Hum. Genet. 88(5), 586-598 (2011).
44. Hall IP, Blakey JD. Genetic association studies in thorax. Thorax 60(5), 357-359 (2005).
45. Fleming L, Murray C, Bansal AT et al. The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. Eur. Respir. J. 46(5), 1322-1333 (2015).
46. Tantisira KG, Lasky-Su J, Harada M et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 365(13), 1173-1183 (2011).
47. Park HW, Dahlin A, Tse S et al. Genetic predictors associated with improvement of asthma symptoms in response to inhaled corticosteroids. J. Allergy Clin. Immunol. 133(3), 664-669.e5 (2014).
48. Tantisira KG, Damask A, Szefler SJ et al. Genomewide association identifies the T gene as a novel asthma pharmacogenetic locus. Am. J. Respir. Crit. Care Med. 185(12), 1286-1291 (2012).
49. Hindorff L, Parkinson H, Welter D et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 42, D1001-D1006 (2014).
50. Zuurhout MJL, Vijverberg SJH, Raaijmakers JAM et al. Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of longacting β2-agonists: results of the PACMAN cohort. Pharmacogenomics 14(16), 1965-1971 (2013).
51. Wechsler ME, Kunselman SJ, Chinchilli VM et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 374(9703), 1754-1764 (2009).
52. Turner S, Francis B, Vijverberg S et al. Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: a meta-analysis stratified by treatment. J. Allergy Clin. Immunol. 138(1), 107-113 (2016).
53. Carroll CL, Schramm CM, Zucker AR. Severe exacerbations in children with mild asthma: characterizing a pediatric phenotype. J. Asthma. 45(6), 513-517 (2008).
54. Leusink M, Vijverberg SJH, Koenderman L et al. Genetic variation in uncontrolled childhood asthma despite ICS treatment. Pharmacogenomics J. 16(2), 158-168 (2015).
55. Vijverberg SJH, Tavendale R, Leusink M et al. Pharmacogenetic analysis of GLCCI1 in three north European pediatric asthma populations with a reported use of inhaled corticosteroids. Pharmacogenomics 15(6), 799-806 (2014).
56. Depner M, Fuchs O, Genuneit J et al. Clinical and epidemiologic phenotypes of childhood asthma. Am. J. Respir. Crit. Care Med. 189(2), 129-138 (2013).
57. Owen RP, Altman RB, Klein TE. PharmGKB and the international warfarin pharmacogenetics consortium: the changing role for pharmacogenomic databases and singledrug pharmacogenetics. Hum. Mutat. 29(4), 456-460 (2008).
58. Paternoster L, Standl M, Chen CM et al. Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. Nat. Genet. 44(2), 187-192 (2012).
59. Moffatt MF, Gut IG, Demenais F et al. A large-scale, consortium-based genomewide association study of asthma. N. Engl. J. Med. 363(13), 1211-1221 (2010).
60. Forno E, Sordillo J, Brehm J et al. Genome-wide interaction study of dust mite allergen on lung function in children with asthma. J Allergy Clin Immunol pii: S0091-6749(17), 30154-30159 (2016).